

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE
MINUTES from Thursday 29th September 2016**

Present:

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – (APC Chair)		Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Paul Chatterton – LPC Representative	✓
Mr Mark Randerson- Head of Medicines Management (NHSD-MMT)	✓	Mr Andrew Houston - Senior Mental Health Pharmacist		Mr M Ahmed - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)		Dr Eric Dale - Consultant Psychiatrist RDaSH FT		<u>DBHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Ms Anne Burton – Non Medical Prescriber Representative (RDaSH DCIS)	✓	Mr Andrew Barker – Chief Pharmacist DBHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBHFT	
Mr Rob Wise – Head of Medicines Management (BCCG)	✓	<u>Doncaster LMC</u>		Dr Mahmoud Al Khoffash – Medical Director representative DBHFT	✓
		Dr Dean Eggitt- LMC Secretary			
		Mr D Gibbons- LMC Deputy		<u>FCMS (When necessary)</u>	
	✓	Dr R Shah – LMC Chair	✓	Mrs Gillian Gregory	

Minutes Only :- Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee

Dr Rupert Suckling & Mr Victor Joseph Public Health England

Mrs Gillian Gregory FCMS

In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)

Agenda Item	Discussion Points	Action By
09/16/1	Apologies Apologies were received from Dr D Crichton, Mrs G Bradley, Dr D Eggitt, Mr L Wilson & Dr E Dale	
09/16/2	Declarations of Interest, Gifts or Hospitality No declarations were received	
09/16/3	Minutes of last meeting The minutes of the last meeting held on the 25 th August 2016 were agreed as a true and accurate record with the following amendments	NHSD-MMT(AM)

	<p>08/16/8.1 The issue of Primary Care resource and whether (not weather) additional funding should be available</p> <p>08/16/17</p> <ul style="list-style-type: none"> The plan is that DBHFT will audit its use in 6 months to assess (not access) the impact. <p>These will be made available on the medicines management website.</p>	
09/16/4.1	Matters Arising	
11/15/8.4	<p>Potential development of SCP/Pathway update for the management of Adult ADHD</p> <p>Further progress will be shared at the October meeting.</p>	RDaSHFT
07/16/8.1	<p>Nottinghamshire APC - Liothyronine.</p> <p>RDaSHFT confirmed that the organisation has not prescribed Liothyronine in Doncaster for a number of years, although they are unable to confirm if any requests have been made to Primary Care to prescribe.</p> <p>DBHFT confirmed that they do not use Liothyronine.</p> <p>Nottinghamshire has categorised Liothyronine as Grey for all indications.</p> <p>NHSD-MMT agreed to check prescribing data to ascertain if there is any on-going prescribing in Primary Care and will follow up if necessary.</p> <p>The Committee discussed categorisation and agreed that:</p> <ul style="list-style-type: none"> For Hypothyroidism the categorisation would be Grey 1,2 For Resistant Depression the categorisation would be Amber-G <p>The Traffic Light Categorisation will be updated accordingly.</p>	<p>NHSD-MMT(AM)</p> <p>NHSD-MMT(MR)</p>
08/16/8.1	<p>Bisphosphonate & Breast Cancer Service</p> <p>The LMC confirmed that there had been no communication with Mrs L Sherburn Head of Partnerships Commissioning regarding the additional work required involved with this service for Primary Care. Feedback will be shared once this has taken place.</p> <p>BCCG advised the Committee that GP Practice's in Bassetlaw have agreed not to support the service.</p>	LMC
08/16/8.2	<p>Publication of Regional Medicines Optimisation Committees (RMOC's) Proposals for Establishment</p> <p>The views of the Committee were collated during the September APC meeting, NHSD-MMT responded on behalf of the Committee. The response was shared with the Committee for information.</p>	
08/16/8.3	<p>STH Neurology Commissioned Pathway</p> <p>Doncaster & Bassetlaw will continue to categorise anticonvulsant medication as Amber G. There are on-going discussions with STH and RDaSHFT to confirm the pathway for the management of patients initiated medication for this condition.</p>	

09/16/5	<p>Traffic Light – Drugs for Review</p> <p>All drugs for review were agreed as proposed, will be updated on the traffic light system and the details included in the T@blet.</p> <p>Conjugated Oestrogens/ Bazedoxifene (DUAVIVE) used in Oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate has been categorised as Green-G non-formulary.</p> <p>Ulipristal acetate (Esmya) has now got an indication for Heavy menstrual bleeding & fibroids and remains as Red 1.</p>	NHSD- MMT(AM)
09/16/6	<p>APC Officers actions</p> <p>All agreed officers actions will be updated on the traffic light system.</p> <p>Hyaluronic acid derivatives will be added to the October Drugs for review. DBHFT confirmed that they have stopped using them for Osteoarthritis</p> <p>Octreotide (Sandostatin + LAR) used in the relief of symptoms associated with neuroendocrine tumours will be added to the October Drugs for review.</p> <p>Degarelix (Firmagon) used in prostate cancer will continue to be categorised as Red, it's status will be reviewed again in 3 months.</p>	NHSD- MMT(AM)
09/16/7	<p>Traffic Light – Additions for Consideration</p> <p>All additions for consideration were agreed as proposed, will be updated on the traffic light system and the details included in the T@blet</p> <p>Glycopyrronium Bromide used to treat peptic ulcers will be categorised as Grey 4 awaiting feedback from Gastroenterology DBHFT.</p> <p>Albiglutide (Eperzan) used in Type 2 Diabetes has been categorised as Green G – non formulary</p> <p>Bosutinib (Bosulif) used in Myeloid leukaemia has been categorised as Red 1,2,3</p> <p>Ibandronic acid 50mg oral used in Post-menopausal women with Breast Cancer has been categorised as Amber-G, however the Committee agreed not to enact the new line for Ibandronic acid at this time. This will be done following the meeting with the LMC & Mrs L Sherburn Head of Partnerships Commissioning. (Section 08/16/8.1 of the minutes).</p>	NHSD- MMT(AM)
09/16/8	<p>New Business</p>	
09/16/8.1	<p>Dementia: NICE TA 217 & CG42</p> <p>NHSD-MMT met with CCG Dementia Leads to discuss the NICE guidance suggesting that treatments may be initiated in Primary Care. The outcome of the meeting confirmed that the pathway in place at present is working well and there didn't appear to be any problems identified.</p> <p>RDaSHFT confirmed that they will update the Shared Care Paperwork to include the slight changes in the updated CG42, Dementia: supporting people with dementia and their carers in health and social care. The shared care paperwork and any local pathway update will be brought back to the next meeting.</p>	RDaSHFT
09/16/8.2	<p>Antipsychotic clinical management and prescribing pathway</p> <p>RDaSHFT and the LMC have met to discuss concerns regarding the clinical management and prescribing pathway development.</p>	RDaSHFT

	Communication will continue and the Clinical Reference Group will be discussing it in November.	
09/16/9	DBHFT D&TC Update No minutes available	
09/16/10	Formulary Liaison Group Update No minutes available	
09/16/11	Doncaster Prisons Drug & Therapeutic Committee No minutes available	
09/16/12	RDASH FT & Medicines Management Committee update The minutes of the meetings held in June & August 2016 were received by the Committee	
09/16/13	Barnsley Area Prescribing Committee Update No minutes available	
09/16/14	Rotherham Area Prescribing Committee update The minutes of the meetings held in June 2016 were received by the Committee	
09/16/15	Sheffield Area Prescribing Committee Update The minutes of the meetings held in January, February, March, May & June were received by the Committee	
09/16/16	Nottinghamshire Area Prescribing Committee Update No minutes available	
09/16/17	Any Other Business <ul style="list-style-type: none"> The Committee was advised of problem when trying to obtain drugs in accordance with the Pre-emptive Prescribing for the Last Days of Life document. NHSD-MMT agreed to feed the concerns back to the End of Life Group. The Committee was advised that RDASHFT was hosting a meeting to develop a policy to support Community Nurses when involved in patient care where there is co-administration of medication by a carer. A pharmacist from NHS-MMT will attend the meeting. 	NHSD-MMT (MR)
09/16/18	Date, time & venue of next meeting 12 noon prompt Thursday 27th October 2016 in Meeting Room 3 Sovereign House	
	12 noon prompt Thursday 24th November 2016 in Meeting Room 3 Sovereign House No December meeting 12 noon prompt Thursday 26 th January 2017 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 23 rd February 2017 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 30 th March 2017 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 27 th April 2017 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 25 th May 2017 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 29 th June 2017 in Meeting Room 3 Sovereign House	